Retinoids for chemoprophylaxis of nonmelanoma skin cancer

Dermatologic Surgery

Volumn 37, Issue 2, 2011, Pages 129-145

  Carr, David R ^a   Trevino, Julian J ^a   Donnelly, Heidi B ^a,b  

^a WRIGHT STATE UNIVERSITY   (United States)

^b Dayton Skin Surgery Center Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; AZATHIOPRINE; BEXAROTENE; CALCIPOTRIOL; CYCLOSPORIN; ETRETIN; ETRETINATE; ISOTRETINOIN; PREDNISONE; PSORALEN; RAPAMYCIN; RETINOIC ACID; RETINOID; RETINOL;

AMINOTRANSFERASE BLOOD LEVEL; ANKYLOSING HYPEROSTOSIS; APPLICATION SITE BURNING; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; APPLICATION SITE STINGING; ARTHRALGIA; BLEPHAROCONJUNCTIVITIS; BRAIN PSEUDOTUMOR; CHEILITIS; CHEMOPROPHYLAXIS; CHRONIC LYMPHATIC LEUKEMIA; CONJUNCTIVITIS; DEPRESSION; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; GENETIC DISORDER; GRAFT RECIPIENT; HEPATITIS; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPEROSTOSIS; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LOW DRUG DOSE; MEDICAL LITERATURE; MENTAL DISEASE; MUCOSAL DRYNESS; MYALGIA; NAIL DISEASE; NEUTROPENIA; NIGHT VISION; NONHODGKIN LYMPHOMA; NONHUMAN; NONMELANOMA SKIN CANCER; NOSE MUCOSA DRYNESS; ONYCHOLYSIS; ONYCHORRHEXIS; ORGAN TRANSPLANTATION; OSTEOPOROSIS; PATIENT MONITORING; PHOTOPHOBIA; PRIORITY JOURNAL; PSORIASIS; PUVA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SKIN ABRASION; SKIN CANCER; SKIN DISEASE; SUICIDAL IDEATION; TELOGEN EFFLUVIUM; TERATOGENICITY; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL; ULTRAVIOLET A RADIATION; UNPLEASANT SENSATION; UNSPECIFIED SIDE EFFECT; XEROSIS;

CARCINOMA; HUMANS; RETINOIDS; SKIN NEOPLASMS;

EID: 79951887471     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2010.01842.x     Document Type: Review

References (112)

1. Trakatelli M, Ulrich C, del Marmol V, et al,. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol 2007; 156 (Suppl 3): 1-7.
2. Higashi MK, Veenstra DL, Langley PC., Health economic evaluation of non-melanoma skin cancer and actinic (Pubitemid 38241495)
3. Wolverton SE., Retinoids. In:, Wolverton SE, Wilkins JK, editors. Systemic Drugs for Skin Diseases. Philadelphia: WB Saunders; 1991. pp. 187-218.
4. Patton TJ, Zirwas MJ, Wolverton SE., Systemic retinoids. In:, Wolverton SE, editor. Comprehensive Dermatologic Drug Therapy. 2nd ed. London: Elsevier; 2007: 275-300.
5. Rogers HW, Weinstock MA, Harris AR, et al,. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010; 146: 283-7.
6. Otley CC, Stasko T, Tope WD, Lebwohl M., Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg 2006; 32: 562-8.
7. Kovach BT, Murphy G, Otley CC, et al,. Oral retinoids for chemoprevention of skin cancers in organ transplant recipients: results of a survey. Transplant Proc 2006; 38: 1366-8.
8. Moloney FJ, Comber H, O'Lorcain P, et al,. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006; 154: 498-504. (Pubitemid 43382659)
9. Rigel DS, Cockerell CJ, Carucci J, Wharton J, Actinic keratosis, basal cell carcinoma, and squamous cell carcinoma. In:, Bolognia J, editor. Dermatology. 2nd ed. London: Elsevier; 2008. pp. 1641-1659.
10. Caforio AL, Fortina AB, Piaserico S, et al,. Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation 2000; 102 (19 Suppl 3): III222-7.
11. Fortina AB, Caforio AL, Piaserico S, et al,. Skin cancer in heart transplant recipients: frequency and risk factor analysis. J Heart Lung Transplant 2000; 19: 249-55.
12. Naldi L, Fortina AB, Lovati S, et al,. Risk of nonmelanoma skin cancer in Italian organ transplant recipients: a registry-based study. Transplantation 2000; 70: 1479-84.
13. Geusau A, Dunkler D, Messeritsch E, et al,. Non-melanoma skin cancer and its risk factors in an Austrian population of heart transplant recipients receiving induction therapy. Int J Dermatol 2008; 47: 918-25.
14. Rubel JR, Milford EL, Abdi R., Cutaneous neoplasms in renal transplant recipients. Eur J Dermatol 2002; 12: 532-5. (Pubitemid 35440787)
15. Carroll RP, Ramsay HM, Fryer AA, et al,. Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: a prospective study in Queensland, Australia. Am J Kidney Dis 2003; 41: 676-83.
16. Ulrich C, Schmook T, Sachse MM, et al,. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. Dermatol Surg 2004; 30 (4 Pt 2): 622-7. (Pubitemid 38525892)
17. Jensen P, Hansen S, Moller B, et al,. Are renal transplant recipients on CsA-based immunosuppressive regimens more likely to develop skin cancer than those on azathioprine and prednisolone? Transplant Proc 1999; 31: 1120. (Pubitemid 29127835)
18. Marcen R, Pascual J, Tato AM, et al,. Influence of immunosuppression on the prevalence of cancer after kidney transplantation. Transplant Proc 2003; 35: 1714-6. (Pubitemid 37093684)
19. Glover MT, Deeks JJ, Raftery MJ, et al,. Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet 1997; 349: 398. (Pubitemid 27077671)
20. Campistol JM., Minimizing the risk of posttransplant malignancy. Transplant Proc 2008; 40 (10 Suppl): S40-3.
21. Luan FL, Ding R, Sharma VK, et al,. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003; 63: 917-26. (Pubitemid 36315569)
22. Campistol JM, Albanell J, Arns W, et al,. Use of proliferation signal inhibitors in the management of post-transplant malignancies-clinical guidance. Nephrol Dial Transplant 2007; 22 (Suppl 1): i36-41. (Pubitemid 47073743)
23. Mita MM, Mita A, Rowinsky EK., Mammalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer 2003; 4: 126-37.
24. Schena FP, Pascoe MD, Alberu J, et al,. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-42.
25. Campistol JM, Eris J, Oberbauer R, et al,. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581-9.
26. Porras B, Costner M, Friedman-Kien AE, Cockerell CJ., Update on cutaneous manifestations of HIV infection. Med Clin North Am 1998; 82: 1033-80, v. (Pubitemid 28433813)
27. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM., Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67. (Pubitemid 47017468)
28. Crum-Cianflone N, Hullsiek KH, Satter E, et al,. Cutaneous malignancies among HIV-infected persons. Arch Intern Med 2009; 169: 1130-8.
29. Stern RS, Thibodeau LA, Kleinerman RA, et al,. Risk of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis. N Engl J Med 1979; 300: 809-13. (Pubitemid 9165020)
30. Stern RS, Laird N, Melski J, et al,. Cutaneous squamous-cell carcinoma in patients treated with PUVA. N Engl J Med 1984; 310: 1156-61. (Pubitemid 14135391)
31. Nijsten TE, Stern RS., The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol 2003; 121: 252-8. (Pubitemid 36969897)
32. Stern RS., Psoralen and ultraviolet a light therapy for psoriasis. N Engl J Med 2007; 357: 682-90.
33. Lim JL, Stern RS., High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients. J Invest Dermatol 2005; 124: 505-13. (Pubitemid 40381572)
34. Marcil I, Stern RS., Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001; 358: 1042-5. (Pubitemid 32925124)
35. Nguyen T, J Y, editors. Squamous Cell Carcinoma. Philidelphia: Elsevier; 2005.
36. Agnew KL, Ruchlemer R, Catovsky D, et al,. Cutaneous findings in chronic lymphocytic leukaemia. Br J Dermatol 2004; 150: 1129-35. (Pubitemid 38932282)
37. Levi F, Randimbison L, Te VC, La Vecchia C., Non-Hodgkin's lymphomas, chronic lymphocytic leukaemias and skin cancers. Br J Cancer 1996; 74: 1847-50. (Pubitemid 26401911)
38. Adami J, Frisch M, Yuen J, et al,. Evidence of an association between non-Hodgkin's lymphoma and skin cancer. BMJ 1995; 310: 1491-5.
39. Dasanu CA, Alexandrescu DT., Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia. MedGenMed 2007; 9: 35.
40. Kraemer KH, Lee MM, Scotto J., Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol 1987; 123: 241-50. (Pubitemid 17002499)
41. Norgauer J, Idzko M, Panther E, et al,. Xeroderma pigmentosum. Eur J Dermatol 2003; 13: 4-9. (Pubitemid 36228497)
42. Fine J, Johnson L, Suchindran C, et al., editors. Cancer and inherited epidermolysis bullosa: lifetable analyses of the National Epidermolysis Bullosa Registry study population. Baltimore: Johns Hopkins University Press; 1999.
43. Koo J, Nguyen Q, Gambla C., Advances in psoriasis therapy. Adv Dermatol 1997; 12: 47-72; discussion 3.
44. Xiao JH, Durand B, Chambon P, Voorhees JJ., Endogenous retinoic acid receptor (RAR)-retinoid X receptor (RXR) heterodimers are the major functional forms regulating retinoid-responsive elements in adult human keratinocytes. Binding of ligands to RAR only is sufficient for RAR-RXR heterodimers to confer ligand-dependent activation of hRAR beta 2/RARE (DR5). J Biol Chem 1995; 270: 3001-11.
45. Lens M, Medenica L., Systemic retinoids in chemoprevention of non-melanoma skin cancer. Expert Opin Pharmacother 2008; 9: 1363-74. (Pubitemid 351877519)
46. Mollard R, Viville S, Ward SJ, et al,. Tissue-specific expression of retinoic acid receptor isoform transcripts in the mouse embryo. Mech Dev 2000; 94: 223-32. (Pubitemid 30332406)
47. Davidovici BB, Tuzun Y, Wolf R., Retinoid receptors. Dermatol Clin 2007; 25: 525-30, viii. (Pubitemid 47454683)
48. Fisher GJ, Talwar HS, Xiao JH, et al,. Immunological identification and functional quantitation of retinoic acid and retinoid X receptor proteins in human skin. J Biol Chem 1994; 269: 20629-35. (Pubitemid 24260474)
49. Cheepala SB, Syed Z, Trutschl M, et al,. Retinoids and skin: microarrays shed new light on chemopreventive action of all-trans retinoic acid. Mol Carcinog 2007; 46: 634-9.
50. Verma AK., Inhibition of both stage I and stage II mouse skin tumour promotion by retinoic acid and the dependence of inhibition of tumor promotion on the duration of retinoic acid treatment. Cancer Res 1987; 47: 5097-101. (Pubitemid 17146479)
51. Syed Z, Cheepala SB, Gill JN, et al,. All-trans retinoic acid suppresses Stat3 signaling during skin carcinogenesis. Cancer Prev Res (Phila Pa) 2009; 2: 903-11.
52. Langenfeld J, Kiyokawa H, Sekula D, et al,. Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. Proc Natl Acad Sci U S A 1997; 94: 12070-4. (Pubitemid 27467844)
53. Spinella MJ, Freemantle SJ, Sekula D, et al,. Retinoic acid promotes ubiquitination and proteolysis of cyclin D1 during induced tumor cell differentiation. J Biol Chem 1999; 274: 22013-8.
54. Dragnev KH, Freemantle SJ, Spinella MJ, Dmitrovsky E., Cyclin proteolysis as a retinoid cancer prevention mechanism. Ann N Y Acad Sci 2001; 952: 13-22. (Pubitemid 34060006)
55. Mrass P, Rendl M, Mildner M, et al,. Retinoic acid increases the expression of p53 and proapoptotic caspases and sensitizes keratinocytes to apoptosis: a possible explanation for tumor preventive action of retinoids. Cancer Res 2004; 64: 6542-8.
56. Huang C, Ma WY, Dawson MI, et al,. Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc Natl Acad Sci U S A 1997; 94: 5826-30. (Pubitemid 27241856)
57. Cheepala SB, Yin W, Syed Z, et al,. Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion. Mol Cancer 2009; 8: 27.
58. Carneiro RV, Sotto MN, Azevedo LS, et al,. Acitretin and skin cancer in kidney transplanted patients. clinical and histological evaluation and immunohistochemical analysis of lymphocytes, natural killer cells and Langerhans' cells in sun exposed and sun protected skin. Clin Transplant 2005; 19: 115-21. (Pubitemid 40227862)
59. Smit JV, de Sevaux RG, Blokx WA, et al,. Acitretin treatment in (pre)malignant skin disorders of renal transplant recipients: histologic and immunohistochemical effects. J Am Acad Dermatol 2004; 50: 189-96.
60. Bellman BA, Eaglstein WH, Miller J., Low dose isotretinoin in the prophylaxis of skin cancer in renal transplant patients. Transplantation 1996; 61: 173. (Pubitemid 26033400)
61. Gibson GE, O'Grady A, Kay EW, Murphy GM., Low-dose retinoid therapy for chemoprophylaxis of skin cancer in renal transplant recipients. J Eur Acad Dermatol Venereol 1998; 10: 42-7. (Pubitemid 28076354)
62. Rook AH, Jaworsky C, Nguyen T, et al,. Beneficial effect of low-dose systemic retinoid in combination with topical tretinoin for the treatment and prophylaxis of premalignant and malignant skin lesions in renal transplant recipients. Transplantation 1995; 59: 714-9.
63. Kelly JW, Sabto J, Gurr FW, Bruce F., Retinoids to prevent skin cancer in organ transplant recipients. Lancet 1991; 338: 1407.
64. Shuttleworth D, Marks R, Griffin PJ, Salaman JR., Treatment of cutaneous neoplasia with etretinate in renal transplant recipients. Q J Med 1988; 68: 717-25.
65. McKenna DB, Murphy GM., Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 1999; 140: 656-60.
66. de Sévaux RG, Smit JV, de Jong EM, et al,. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin. J Am Acad Dermatol 2003; 49: 407-12.
67. George R, Weightman W, Russ GR, et al,. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002; 43: 269-73. (Pubitemid 35365416)
68. McNamara IR, Muir J, Galbraith AJ., Acitretin for prophylaxis of cutaneous malignancies after cardiac transplantation. J Heart Lung Transplant 2002; 21: 1201-5. (Pubitemid 35300466)
69. Bavinck JN, Tieben LM, Van der Woude FJ, et al,. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13: 1933-8.
70. Yuan ZF, Davis A, Macdonald K, Bailey RR., Use of acitretin for the skin complications in renal transplant recipients. N Z Med J 1995; 108: 255-6.
71. Vandeghinste N, De Bersaques J, Geerts ML, Kint A., Acitretin as cancer chemoprophylaxis in a renal transplant recipient. Dermatology 1992; 185: 307-8.
72. Harwood CA, Leedham-Green M, Leigh IM, Proby CM., Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study. Arch Dermatol 2005; 141: 456-64. (Pubitemid 40547404)
73. Euvrard S, Kanitakis J, Claudy A., Topical retinoids for the management of dysplastic epithelial lesions. Montrouge: John Libbey Eurotext; 1998.
74. Euvrard S, Verschoore M, Touraine J., Topical retinoids for warts and keratoses in transplant patients. Lancet 1992; 340: 48-9.
75. Smit JV, Cox S, Blokx WA, et al,. Actinic keratoses in renal transplant recipients do not improve with calcipotriol cream and all-trans retinoic acid cream as monotherapies or in combination during a 6-week treatment period. Br J Dermatol 2002; 147: 816-8. (Pubitemid 35286183)
76. Kraemer KH, DiGiovanna JJ, Moshell AN, et al,. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318: 1633-7.
77. Kraemer KH, DiGiovanna JJ, Peck GL., Chemoprevention of skin cancer in xeroderma pigmentosum. J Dermatol 1992; 19: 715-8. (Pubitemid 23119632)
78. Peck GL, DiGiovanna JJ, Sarnoff DS, et al,. Treatment and prevention of basal cell carcinoma with oral isotretinoin. J Am Acad Dermatol 1988; 19 (1 Pt 2): 176-85.
79. Tangrea JA, Edwards BK, Taylor PR, et al,. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-basal cell carcinoma study group. J Natl Cancer Inst 1992; 84: 328-32.
80. Levine N, Moon TE, Cartmel B, et al,. Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest skin cancer prevention study group. Cancer Epidemiol Biomarkers Prev 1997; 6: 957-61.
81. Moon TE, Levine N, Cartmel B, et al,. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest skin cancer prevention study group. Cancer Epidemiol Biomarkers Prev 1997; 6: 949-56.
82. Lebwohl M, Tannis C, Carrasco D., Acitretin suppression of squamous cell carcinoma: case report and literature review. J Dermatol Treat 2003; 14 (Suppl 2): 3-6.
83. van de Kerkhof PC, de Rooij MJ., Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: response to long-term acitretin maintenance. Br J Dermatol 1997; 136: 275-8. (Pubitemid 27062738)
84. Sanchez-Conejo-Mir J, Camacho F., Nevoid basal cell carcinoma syndrome: combined etretinate and surgical treatment. J Dermatol Surg Oncol 1989; 15: 868-71.
85. Hodak E, Ginzburg A, David M, Sandbank M., Etretinate treatment of the nevoid basal cell carcinoma syndrome. Therapeutic and chemopreventive effect. Int J Dermatol 1987; 26: 606-9. (Pubitemid 17160093)
86. Cristofolini M, Zumiani G, Scappini P, Piscioli F., Aromatic retinoid in the chemoprevention of the progression of nevoid basal-cell carcinoma syndrome. J Dermatol Surg Oncol 1984; 10: 778-81. (Pubitemid 14000128)
87. Viglioglia PA., Therapeutic evaluation of the oral retinoid Ro 10-9359 in several non-psoriatic dermatoses. Br J Dermatol 1980; 103: 483-7. (Pubitemid 11243270)
88. Schnitzler L, Schubert B, Verret JL., [Evaluation of oral retinoid preventive action on human cutaneous epitheliomas (author's transl)]. Ann Dermatol Venereol 1980; 107: 657-63. (Pubitemid 10020456)
89. Verret JL, Avenel M, Belperron P, Duboz A., [Basocellular nevomatosis trial of preventing carcinomatous transformations with an aromatic retinoid]. Ann Dermatol Venereol 1982; 109: 821-2.
90. Odom R., Managing actinic keratoses with retinoids. J Am Acad Dermatol 1998; 39 (2 Pt 3): S74-8. (Pubitemid 28367291)
91. Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC., Current use and future potential role of retinoids in dermatology. Drugs 1997; 53: 358-88. (Pubitemid 27117359)
92. Leyden JJ., The role of isotretinoin in the treatment of acne: personal observations. J Am Acad Dermatol 1998; 39 (2 Pt 3): S45-9.
93. Murray HE, Anhalt AW, Lessard R, et al,. A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study. J Am Acad Dermatol 1991; 24: 598-602.
94. Boer J, van Gemert MJ., Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol 1999; 40: 73-6. (Pubitemid 29051027)
95. Desai A, Kartono F, Del Rosso JQ., Systemic retinoid therapy: a status report on optimal use and safety of long-term therapy. Dermatol Clin 2007; 25: 185-93, vi.
96. Tangrea JA, Adrianza E, Helsel WE, et al,. Clinical and laboratory adverse effects associated with long-term, low-dose isotretinoin: incidence and risk factors. The isotretinoin-basal cell carcinomas study group. Cancer Epidemiol Biomarkers Prev 1993; 2: 375-80.
97. Roenigk HH Jr., Liver toxicity of retinoid therapy. J Am Acad Dermatol 1988; 19 (1 Pt 2): 199-208.
98. Crockett SD, Gulati A, Sandler RS, Kappelman MD., A causal association between isotretinoin and inflammatory bowel disease has yet to be established. Am J Gastroenterol 2009; 104: 2387-93.
99. David M, Hodak E, Lowe NJ., Adverse effects of retinoids. Med Toxicol Adverse Drug Exp 1988; 3: 273-88.
100. Ellis CN, Pennes DR, Hermann RC, et al,. Long-term radiographic follow-up after isotretinoin therapy. J Am Acad Dermatol 1988; 18: 1252-61.
101. DiGiovanna JJ, Helfgott RK, Gerber LH, Peck GL., Extraspinal tendon and ligament calcification associated with long-term therapy with etretinate. N Engl J Med 1986; 315: 1177-82. (Pubitemid 17056647)
102. DiGiovanna JJ., Isotretinoin effects on bone. J Am Acad Dermatol 2001; 45: S176-82.
103. Halverstam CP, Zeichner J, Lebwohl M., Lack of significant skeletal changes after long-term, low-dose retinoid therapy: case report and review of the literature. J Cutan Med Surg 2006; 10: 291-9.
104. Fraunfelder FT, Fraunfelder FW, Edwards R., Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol 2001; 132: 299-305. (Pubitemid 32768596)
105. Denis P, Nordmann JP, Saiag P, et al,. [Chronic blepharoconjunctivitis during a treatment with acitretin (Soriatane)]. J Fr Ophtalmol 1993; 16: 191-4. (Pubitemid 23144782)
106. Gross EG, Helfgott MA., Retinoids and the eye. Dermatol Clin 1992; 10: 521-31.
107. Weleber RG, Denman ST, Hanifin JM, Cunningham WJ., Abnormal retinal function associated with isotretinoin therapy for acne. Arch Ophthalmol 1986; 104: 831-7. (Pubitemid 16114928)
108. Sieving PA, Chaudhry P, Kondo M, et al,. Inhibition of the visual cycle in vivo by 13-cis retinoic acid protects from light damage and provides a mechanism for night blindness in isotretinoin therapy. Proc Natl Acad Sci U S A 2001; 98: 1835-40. (Pubitemid 32165584)
109. Egger SF, Huber-Spitzy V, Bohler K, et al,. Ocular side effects associated with 13-cis-retinoic acid therapy for acne vulgaris: clinical features, alterations of tearfilm and conjunctival flora. Acta Ophthalmol Scand 1995; 73: 355-7.
110. Lammer EJ, Chen DT, Hoar RM, et al,. Retinoic acid embryopathy. N Engl J Med 1985; 313: 837-41. (Pubitemid 15250197)
111. Geiger JM, Walker M., Is there a reproductive safety risk in male patients treated with acitretin (neotigason/soriatane? Dermatology 2002; 205: 105-7.
112. Kontaxakis VP, Skourides D, Ferentinos P, et al,. Isotretinoin and psychopathology: a review. Ann Gen Psychiatry 2009; 8: 2.